Amneal Pharmaceuticals, Inc.

NasdaqGS:AMRX Stock Report

Market Cap: US$4.2b

Amneal Pharmaceuticals Future Growth

Future criteria checks 4/6

Amneal Pharmaceuticals is forecast to grow earnings and revenue by 79.9% and 7.5% per annum respectively. EPS is expected to grow by 77.7% per annum. Return on equity is forecast to be 68.1% in 3 years.

Key information

79.9%

Earnings growth rate

77.70%

EPS growth rate

Pharmaceuticals earnings growth12.9%
Revenue growth rate7.5%
Future return on equity68.09%
Analyst coverage

Low

Last updated07 Jan 2026

Recent future growth updates

Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 08
Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Recent updates

Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks

Dec 18

Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Nov 30
Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point

Nov 14
Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point

Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 08
Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S

Jul 24
Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S
User avatar

CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market

The strategic collaboration in GLP-1 therapies and biosimilars expands market reach, poised to drive significant future revenue growth.

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued

Mar 19

There's No Escaping Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Muted Revenues

Feb 17
There's No Escaping Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Muted Revenues

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Nov 10
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Jul 10

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Apr 15
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Mar 19
Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Earnings and Revenue Growth Forecasts

NasdaqGS:AMRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20273,485N/A5004213
12/31/20263,211642862914
12/31/20253,011603463354
9/30/20252,9356237328N/A
6/30/20252,8533262351N/A
3/31/20252,830-13233307N/A
12/31/20242,794-117220295N/A
9/30/20242,680-184229313N/A
6/30/20242,598-175176252N/A
3/31/20242,495-169124201N/A
12/31/20232,394-84276346N/A
9/30/20232,38610137186N/A
6/30/20232,312-2114199N/A
3/31/20232,272-135-584N/A
12/31/20222,212-130-2565N/A
9/30/20222,139-13253152N/A
6/30/20222,122-13480140N/A
3/31/20222,0982161214N/A
12/31/20212,09411189242N/A
9/30/20212,06714219285N/A
6/30/20212,0589176247N/A
3/31/20211,987-17408478N/A
12/31/20201,99391313379N/A
9/30/20201,88062183222N/A
6/30/20201,739-194283317N/A
3/31/20201,679-19971159N/A
12/31/20191,626-362-962N/A
9/30/20191,727-339200312N/A
6/30/20191,825-67N/A234N/A
3/31/20191,834-69N/A115N/A
12/31/20181,663-21N/A250N/A
9/30/20181,459155N/A56N/A
6/30/20181,237149N/A67N/A
3/31/20181,083168N/A192N/A
12/31/20171,034168N/A234N/A
9/30/20171,03954N/A205N/A
12/31/20161,018207N/A115N/A
12/31/2015866169N/A105N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMRX's forecast earnings growth (79.9% per year) is above the savings rate (3.3%).

Earnings vs Market: AMRX's earnings (79.9% per year) are forecast to grow faster than the US market (16% per year).

High Growth Earnings: AMRX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AMRX's revenue (7.5% per year) is forecast to grow slower than the US market (10.5% per year).

High Growth Revenue: AMRX's revenue (7.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AMRX's Return on Equity is forecast to be very high in 3 years time (68.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/08 06:35
End of Day Share Price 2026/01/08 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Amneal Pharmaceuticals, Inc. is covered by 19 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Glen SantangeloBarclays
Gary NachmanBMO Capital Markets Equity Research
David BuckB. Riley Securities, Inc.